Education
About Us
Working with TipRanks
Follow Us
Brainsway Ltd (BWAY)
NASDAQ:BWAY
Earnings Data
Report Date
Aug 06, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0.03Last Year’s EPS
0.02Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 13, 2025
|% Change Since: 12.23%
|Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment|Positive
The earnings call reflected strong growth in both revenue and system shipments, indicating robust demand for BrainsWay's Deep TMS systems. The company is making significant strides in clinical advancements and maintains a strong financial position with positive guidance for the year. However, increased operating expenses and potential geopolitical risks are concerns that need monitoring.Company Guidance
During the BrainsWay First Quarter 2025 earnings call, the company reported a revenue of $11.5 million, marking a 27% increase year-over-year. They shipped 81 Deep TMS systems, a 42% increase from Q1 2024, and maintained a gross margin of 75%. The company has a backlog and remaining performance obligations totaling nearly $60 million, reflecting strong demand and future growth visibility. BrainsWay's full-year 2025 revenue guidance is between $49 million and $51 million, representing a 20% to 24% growth over 2024, with anticipated operating income of 3% to 4% and adjusted EBITDA of 11% to 12%. The company is also focusing on expanding its market presence, enhancing customer engagement through multi-year agreements, and advancing its R&D roadmap to unlock new treatment indications.Significant Revenue Growth
BrainsWay reported $11.5 million in revenue for Q1 2025, marking a 27% increase year-over-year.
Increased System Shipments
The company shipped 81 Deep TMS systems, a 42% increase compared to the first quarter of 2024.
Strong Backlog and Future Visibility
BrainsWay has a backlog and remaining performance obligation totaling nearly $60 million, indicating clear visibility into future growth.
Clinical Advancements
The first TMS therapy approved for OCD and the first TMS device cleared by the FDA for anxious depression. Over 60% positive response rate for OCD patients.
Solid Financial Performance
Reported gross margin of 75%, increased operating income, and adjusted EBITDA margin, with positive cash flow from operations.
Positive Financial Guidance
Reiterating full-year 2025 financial guidance of $49 million to $51 million in revenue, representing 20% to 24% growth over 2024.
---
BWAY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
BWAY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 13, 2025 | $8.83 | $9.81 | +11.10% |
Mar 11, 2025 | $9.19 | $9.62 | +4.68% |
Nov 12, 2024 | $10.80 | $9.70 | -10.19% |
Aug 06, 2024 | $6.39 | $6.89 | +7.82% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Brainsway Ltd (BWAY) report earnings?
Brainsway Ltd (BWAY) is schdueled to report earning on Aug 06, 2025, TBA Not Confirmed.
What is Brainsway Ltd (BWAY) earnings time?
Brainsway Ltd (BWAY) earnings time is at Aug 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BWAY EPS forecast?
BWAY EPS forecast for the fiscal quarter 2025 (Q2) is 0.03.
---